Figure 1. Study design. AE = adverse events; clinic = self-administration of belimumab SC at the clinic; home = self-administration of belimumab SC at home; IV = intravenous; PK = blood sample taken for pharmacokinetic analysis prior to belimumab administration; SC = subcutaneous.